Cardio-microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C-MIC II open-label randomized controlled trial.

Upon review of the unblinded data, the independent data monitoring committee observed a highly significant improvement in the primary endpoint ( p < 0.0001), along with favourable trends across multiple secondary endpoints, and recommended stopping the study in October 2023.

also in 132,142 other papers

While this difference did not reach statistical significance, the directional change was consistent with other functional outcomes.

also in 111,027 other papers